Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and FUJI YAKUHIN CO., LTD.n(Headquarters: Saitama, CEO: Masayuki Takayanagi, “FUJI YAKUHIN”) announced today that they havenconcluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia andngout discovered by FUJI YAKUHIN, for development and distribution in five ASEAN (Association ofnSoutheast Asian Nations) member states: Indonesia, Malaysia, Myanmar, the Philippines, and Thailand. Thisnagreement conclusion will lead to an expansion into Southeast Asia of an agreement regarding dotinurad innChina concluded by Eisai and FUJI YAKUHIN in February 2020.